Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROLITE vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Electrolyte replenishment,Hypokalemia,Hypomagnesemia
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
1 tablet orally every 8 hours with or without food.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Terminal elimination half-life is 12–15 hours in healthy adults, allowing twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Not metabolized; excreted unchanged by kidneys.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Renal excretion accounts for approximately 70% of the dose, primarily as unchanged drug. Fecal elimination constitutes about 30%, with a minor contribution from biliary excretion (<10%).
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
98% bound to serum albumin. Minimal binding to alpha-1-acid glycoprotein.
Approximately 45-50% bound primarily to albumin.
0.15–0.20 L/kg, indicating distribution primarily into extracellular fluid. Does not extensively penetrate tissues or cross the blood-brain barrier significantly.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Oral: 90% (well absorbed, minimal first-pass metabolism). Intramuscular: 100% (complete absorption).
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
GFR 30-50 m L/min: 1 tablet every 12 hours; GFR 15-29 m L/min: 1 tablet every 24 hours; GFR <15 m L/min: contraindicated.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
Child-Pugh A: no adjustment; Child-Pugh B: 1 tablet every 12 hours; Child-Pugh C: contraindicated.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
Weight <30 kg: 10 mg/kg/dose orally every 8 hours; Weight ≥30 kg: same as adult dosing.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
No specific dose adjustment required based on age alone; monitor renal function and adjust per renal adjustment guidelines.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
None
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Use with caution in renal impairment; monitor serum electrolytes; avoid in patients with hyperkalemia or hypermagnesemia.
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia, hypermagnesemia, severe renal impairment.
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) unless monitored. Salt substitutes (e.g., KCl) increase hyperkalemia risk. Take with food to minimize GI upset.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No specific data but theoretical risk minimal due to poor oral absorption. Second/Third trimester: No known adverse fetal effects; used therapeutically for preeclampsia prevention at higher doses (IV magnesium sulfate, not this oral form).
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Magnesium is excreted into breast milk; however, oral magnesium citrate is poorly absorbed. Infant exposure is likely minimal. M/P ratio not established. Use caution with high doses as diarrhea in mother may occur, but breastfeeding is generally considered compatible.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
No dosage adjustment typically required for oral magnesium citrate during pregnancy. However, gastrointestinal absorption may be slightly decreased; no change recommended. Avoid high doses due to risk of maternal diarrhea and electrolyte imbalance.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
Microlite is a potassium-magnesium supplement used for electrolyte repletion. Monitor renal function prior to initiation; avoid in severe renal impairment (Cr Cl <30 m L/min). Use cautiously with ACE inhibitors, ARBs, or potassium-sparing diuretics due to hyperkalemia risk. Infuse slowly if intravenous to avoid phlebitis.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
Take with food or after meals to reduce gastrointestinal irritation.,Do not crush or chew extended-release tablets; swallow whole.,Report muscle weakness, fatigue, or irregular heartbeat immediately.,Avoid salt substitutes containing potassium unless directed by your healthcare provider.,Store at room temperature away from moisture and heat.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
No interactions on record
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROLITE vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
MICROLITE is a Electrolyte Supplement that works by MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROLITE and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROLITE is: 1 tablet orally every 8 hours with or without food.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROLITE and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROLITE is classified as Category C. MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No . CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.